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Background:  In acute myocardial infarction (AMI), interleukin-1 (IL-1), a pro-inflammatory cytokine and mediator of innate inflammatory 
responses, promotes adverse cardiac remodeling and heart failure. The aim of this study was to evaluate the effects of a high affinity anti-murine 
IL-1β monoclonal antibody (XMA052 MG1K) on cardiac remodeling after experimental AMI in the mouse.
Methods:  ICR mice (n=24) were randomly assigned to treatment with XMA052 MG1K (0.05, 0.5 or 5 mg/kg given immediately after surgery and 
again 7 days later), a control murine IgG (0.5 mg/kg) or normal saline solution following experimental acute AMI induced by coronary artery ligation. 
Transthoracic echocardiography was performed at baseline and 14 days after surgery to assess LV end-diastolic (LVEDD) and systolic (LVESD) 
diameters, and LV fractional shortening (LVFS).
Results:  Treatment with XMA052 MG1K 0.5 mg/kg or 5 mg/kg, but not the 0.05 mg/kg, resulted in significantly >40% smaller increases in LVEDD, 
>30% smaller increase in LVESD, and >20% greater preservations in LVFS up to day 28, compared to the IgG control or saline, without signs of 
cardiac toxicity. The Figure shows changes in LVESD over time.
Conclusions:  These data show that a novel high affinity anti-IL-1β antibody ameliorates cardiac remodeling after experimental AMI in the mouse 
and are consistent with the role of the IL-1β isoform in post-AMI remodeling. This study opens the way to use ananti-IL-1β antibody to reduce heart 
failure after AMI.
